The obesity paradox has been recently proposed in various heart disease treatments including percutaneous coronary intervention. However, no study has yet examined the effect of the obesity paradox on patients with diabetes mellitus (DM). Our aim was to evaluate the impact of body mass index (BMI) on the mid-term restenosis rate of sirolimus-eluting stent (SES) implantation in patients with and without DM. Furthermore, we evaluated the differences between de novo and in-stent restenosis lesions. Methods: We evaluated 2,949 patients, 1211 (41.0%) of whom had had DM and had undergone SES implantation (excluding hemodialysis patients and hybrid stenting) between November 2002 and December 2008. The patients were classified as under/ normal weight (BMIϾ25) and overweight (BMIՆ25). We compared the restenosis rates with SES within 8 months between de novo and in-stent restenosis lesions based on BMI and the presence or absence of DM. Results: Among patients with DM, the group of BMIՆ25 (439 patients) had significantly reduced restenosis rate than that of BMIϾ25 (577 patients) in de novo lesions (BMIϾ25, 13.1%; BMIՆ25, 7.8%; pϭ0.001), whereas no significant difference was present between the two BMI groups in in-stent restenosis lesions (BMIϾ25, 19.4%; BMIՆ25, 16.5%; pϭ0.981). In contrast, among patients without DM, there was no significant difference in the restenosis rates between the two BMI groups in both de novo lesions (BMIϾ25, 6.1%; BMIՆ25, 5.3%; pϭ0.433) and in-stent lesions (BMIϾ25, 14.6%; BMIՆ25, 14.5%; pϭ0.535).
Background: The obesity paradox has been recently proposed in various heart disease treatments including percutaneous coronary intervention. However, no study has yet examined the effect of the obesity paradox on patients with diabetes mellitus (DM). Our aim was to evaluate the impact of body mass index (BMI) on the mid-term restenosis rate of sirolimus-eluting stent (SES) implantation in patients with and without DM. Furthermore, we evaluated the differences between de novo and in-stent restenosis lesions. Methods: We evaluated 2,949 patients, 1211 (41.0%) of whom had had DM and had undergone SES implantation (excluding hemodialysis patients and hybrid stenting) between November 2002 and December 2008. The patients were classified as under/ normal weight (BMIϾ25) and overweight (BMIՆ25). We compared the restenosis rates with SES within 8 months between de novo and in-stent restenosis lesions based on BMI and the presence or absence of DM. Results: Among patients with DM, the group of BMIՆ25 (439 patients) had significantly reduced restenosis rate than that of BMIϾ25 (577 patients) in de novo lesions (BMIϾ25, 13.1%; BMIՆ25, 7.8%; pϭ0.001), whereas no significant difference was present between the two BMI groups in in-stent restenosis lesions (BMIϾ25, 19.4%; BMIՆ25, 16.5%; pϭ0.981). In contrast, among patients without DM, there was no significant difference in the restenosis rates between the two BMI groups in both de novo lesions (BMIϾ25, 6.1%; BMIՆ25, 5.3%; pϭ0.433) and in-stent lesions (BMIϾ25, 14.6%; BMIՆ25, 14.5%; pϭ0.535).
Conclusions:
The obesity paradox was present only in restenosis after SES implantation for de novo lesions in patients with DM. Results: Significantly greater number of flow-limiting lesions (Ն70% diameter stenosis) in DM were located in the distal SFA (71% vs. 22.2%, pϭ0.008) and popliteal artery (38% vs. 8.3%, pϭ0.004) compared to non-DM. Lesion length in DM was longer (DM: 138Ϯ73.3 mm vs. non-DM: 84Ϯ54.7 mm, pϽ0.001), with more grade 3 fluoroscopic calcification (50% vs. 8%; pϭ0.006) and more total occlusions (59% vs. 30.5%, pϭ0.02). Angiographic severity (Bollinger score) was higher in DM (12Ϯ4.85 vs. 9Ϯ4.3 pϭ0.003, Figure 1 ). Mean number of diseased (Ն50% diameter stenosis) run-off vessels in DM and non-DM were 2.53 and 2.36, respectively (pϭ0.04). There was a greater need for bail-out stenting in DM compared to non-DM (93% vs. 33.5%; pϽ0.006) with longer stent lengths used in DM (241.5Ϯ98 mm vs. 195Ϯ116 mm, pϽ0.002). Atherectomy was more frequent in DM (72% vs. 10.7%; pϽ0.008). Overall, 12-month clinical patency rate was 63% in DM and 82% in non-DM (pϽ0.004). Conclusions: DM with claudication have more severe angiographic SFA disease compared to non-DM, greater need for bail-out stenting and lower 12-month clinical patency, indicating the need for dedicated studies in DM. 
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